| References |
|
|
Adhikari S,
Choudhury S,
Mitra PS et al.
(2008)
Targeting base excision repair for chemosensitization.
Anti-Cancer Agents in Medicinal Chemistry
8:
351–357.
|
|
|
Altmeyer M,
Messner S,
Hassa PO,
Fey M and
Hottiger MO
(2009)
Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites.
Nucleic Acids Research
37:
3723–3738.
|
|
|
Bentle MS,
Bey EA,
Dong Y,
Reinicke KE and
Boothman DA
(2006)
New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors.
Journal of Molecular Histology
37:
203–218.
|
|
|
Bowman KJ,
White A,
Golding BT,
Griffin RJ and
Curtin NJ
(1998)
Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.
British Journal of Cancer
78:
1269–1277.
|
|
|
Calabrese CR,
Batey MA,
Thomas HD et al.
(2003)
Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Clinical Cancer Research
9:
2711–2718.
|
|
|
Fishel M and
Kelley M
(2007)
The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target.
Molecular Aspects of Medicine
28:
375–395.
|
|
|
Fishel ML,
He Y,
Smith ML and
Kelley MR
(2007)
Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide.
Clinical Cancer Research
13:
260–267.
|
|
|
Frederick AM,
Davis ML and
Rice KP
(2009)
Inhibition of human DNA polymerase beta activity by the anticancer prodrug Cloretazine.
Biochemical and Biophysical Research Communications
378:
419–423.
|
|
|
Hazan C,
Boudsocq F,
Gervais V et al.
(2008)
Structural insights on the pamoic acid and the 8 kDa domain of DNA polymerase beta complex: towards the design of higher-affinity inhibitors.
BMC Structural Biology
8:
22.
|
|
|
Helleday T,
Petermann E,
Lundin C,
Hodgson B and
Sharma RA
(2008)
DNA repair pathways as targets for cancer therapy.
Nature Reviews. Cancer
8:
193–204.
|
|
|
Helleday T
(2008)
Amplifying tumour-specific replication lesions by DNA repair inhibitors – a new era in targeted cancer therapy.
European Journal of Cancer
44:
921–927.
|
|
|
Horvath EM,
Benko R,
Kiss L et al.
(2009)
Rapid ‘glycaemic swings’ induce nitrosative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus.
Diabetologia
52:
952–961.
|
|
|
Hu HY,
Horton JK,
Gryk MR et al.
(2004)
Identification of small molecule synthetic inhibitors of DNA polymerase beta by NMR chemical shift mapping.
Journal of Biological Chemistry
279:
39736–39744.
|
|
|
Ismail IS,
Ito H,
Mukainaka T et al.
(2003)
Ichthyotoxic and anticarcinogenic effects of triterpenoids from Sandoricum koetjape bark.
Biological and Pharmaceutical Bulletin
26:
1351–1353.
|
|
|
Jiang YL,
Krosky DJ,
Seiple L and
Stivers JT
(2005)
Uracil-directed ligand tethering: an efficient strategy for uracil DNA glycosylase (UNG) inhibitor development.
Journal of the American Chemical Society
127:
17412–17420.
|
|
|
Kelley MR and
Fishel ML
(2008)
DNA repair proteins as molecular targets for cancer therapeutics.
Anti-Cancer Agents in Medicinal Chemistry
8:
417–425.
|
|
|
Khong HT,
Dreisbach L,
Kindler HL et al.
(2007)
A phase 2 study of ARQ 501 in combination with gemcitabine in adult patients with treatment naive, unresectable pancreatic adenocarcinoma.
Journal of Clinical Oncology (Meeting Abstracts)
25:
15017.
|
|
|
Kimler BF,
Schneiderman MH and
Leeper DB
(1978)
Induction of concentration-dependent blockade in the G2 phase of the cell cycle by cancer chemotherapeutic agents.
Cancer Research
38:
809–814.
|
|
|
Lewis C and
Low JA
(2007)
Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
Current Opinion in Investigational Drugs
8:
1051–1056.
|
|
|
Luo MH and
Kelley MR
(2004)
Inhibition of the human apurinic/apyrimidinic endonuclease (Ape1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone.
Anticancer Research
24:
2127–2134.
|
|
|
Madhusudan S and
Hickson ID
(2005)
DNA repair inhibition: a selective tumour targeting strategy.
Trends in Molecular Medicine
11:
503–511.
|
|
|
Maga G and
Hubscher U
(2008)
Repair and translesion DNA polymerases as anticancer drug targets.
Anticancer Agents in Medicinal Chemistry
8:
431–447.
|
|
|
Martin SA,
Lord CJ and
Ashworth A
(2008)
DNA repair deficiency as a therapeutic target in cancer.
Current Opinion in Genetics & Development
18:
80–86.
|
|
|
Pascucci B,
Stucki M,
Jonsson ZO,
Dogliotti E and
Hubscher U
(1999)
Long patch base excision repair with purified human proteins. DNA ligase I as patch size mediator for DNA polymerases delta and epsilon.
Journal of Biological Chemistry
274:
33696–33702.
|
|
|
Peralta-Leal A,
Manuel Rodriguez-Vargas J,
Aguilar-Quesada R et al.
(2009)
PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Free Radical Biology and Medicine
47:
13–26.
|
|
|
Raffoul JJ,
Sarkar FH and
Hillman GG
(2007)
Radiosensitization of prostate cancer by soy isoflavones.
Current Cancer Drug Targets
7:
759–765.
|
|
|
Roukos DH,
Murray S and
Briasoulis E
(2007)
Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer.
Cancer Biology and Therapy
6:
308–312.
|
|
|
Seiple LA,
Cardellina JH II,
Akee R and
Stivers JJ
(2008)
Potent inhibition of human apurinic/apyrimidinic endonuclease 1 by arylstibonic acids.
Molecular Pharmacology
73:
669–677.
|
|
|
Sharma RA and
Dianov GL
(2007)
Targeting base excision repair to improve cancer therapies.
Molecular Aspects of Medicine
28:
345–374.
|
|
|
Simeonov A,
Kulkarni A,
Dorjsuren D et al.
(2009)
Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1.
PLoS ONE
4(6):
e5740.
|
|
|
Southan GJ and
Szabo C
(2003)
Poly(ADP-ribose) polymerase inhibitors.
Current Medicinal Chemistry
10:
321–340.
|
|
|
Szabó G,
Soós P,
Mandera S et al.
(2004)
Ino-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation.
Shock
21:
426–432.
|
|
|
Tentori L and
Graziani G
(2005)
Chemopotentiation by PARP inhibitors in cancer therapy.
Pharmacological Research
52:
25–33.
|
|
|
Tentori L,
Portarena I and
Graziani G
(2002)
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.
Pharmacological Research
45:
73–85.
|
|
|
Thomas HD,
Calabrese CR,
Batey MA et al.
(2007)
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.
Molecular Cancer Therapeutics
6:
945–956.
|
|
|
Yang S,
Irani K,
Heffron SE,
Jurnak F and
Meyskens FL Jr
(2005)
Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor.
Molecular Cancer Therapeutics
4:
1923–1935.
|
|
|
Zawahir Z,
Dayam R,
Deng J,
Pereira C and
Neamati N
(2009)
Pharmacophore guided discovery of small-molecule human apurinic/apyrimidinic endonuclease 1 inhibitors.
Journal of Medicinal Chemistry
52:
20–32.
|
|
|
Zou G and
Maitra A
(2008)
Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration.
Molecular Cancer Therapeutics
7:
2012–2021.
|
| Further Reading |
|
|
Lord CJ and
Ashworth A
(2008)
Targeted therapy for cancer using PARP inhibitors.
Current Opinion in Pharmacology
8(4):
363–369.
|
|
|
Nouspikel T
(2009)
DNA repair in mammalian cells.
Cellular and Molecular Life Sciences
66(6):
994–1009.
|
|
|
Pal SK and
Mortimer J
(2009)
Triple-negative breast cancer: novel therapies and new directions.
Maturitas
63(4):
269–274.
|
|
|
Reed AM,
Fishel ML and
Kelly MR
(2009)
Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation.
Future Oncology
5(5):
713–226.
|
|
|
Sánchez-Pérez I
(2006)
DNA repair inhibitors in cancer treatment.
Clinical and Translational Oncology
8(9):
642–646.
|
